Advertisement 下载google应用的软件
          Pharmaceutical Business review is using cookies

          ContinueLearn More
          Close
          August 3, 2020

          Novartis gets EC nod for Cosentyx drug in paediatric psoriasis

          Novartis has secured approval from the European Commission (EC) for its Cosentyx (secukinumab) to treat moderate-to-severe plaque psoriasis in children and adolescents aged between six and 18 years

          Novartis has secured EC approval for Cosentyx drug in paediatric psoriasis. (Credit: Novartis AG)